EyePoint Pharmaceuticals, Inc. (EYPT) Financial Statements (2024 and earlier)

Company Profile

Business Address 480 PLEASANT STREET
WATERTOWN, MA 02472
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
6/30/2018
6/30/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:144,600211,60044,90922,21438,77616,898
Cash and cash equivalents95,633178,59344,90922,21438,77616,898
Short-term investments48,92865,965    
Other undisclosed cash, cash equivalents, and short-term investments39(32,958)    
Receivables  414104   
Inventory, net of allowances, customer advances and progress billings2,8863,6165,3372,138  
Inventory2,8863,6165,3372,138  
Prepaid expense2,723     
Other current assets782     
Other undisclosed current assets21,81722,11512,76817,3651,133842
Total current assets:172,808237,74563,11841,71739,90917,740
Noncurrent Assets
Operating lease, right-of-use asset6,0382,2522,6103,078
Property, plant and equipment1,360476630357253313
Intangible assets, net (including goodwill)  22,74925,20927,66931,358364
Intangible assets, net (excluding goodwill)  22,74925,20927,66931,358364
Restricted cash and investments150150150150150150
Other undisclosed noncurrent assets      110
Total noncurrent assets:7,54825,62728,59931,25431,761937
TOTAL ASSETS:180,356263,37291,71772,97171,67018,677
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities22,27821,80713,25611,0246,6635,240
Accounts payable5,9197,3854,8114,1922,9401,016
Accrued liabilities16,35914,4228,4456,8323,7234,224
Deferred revenue1,2051,06994515
Debt 10,475  481  
Deferred revenue and credits 50
Other liabilities579782687   
Other undisclosed current liabilities     15,000 
Total current liabilities:34,53723,65814,88811,52021,6635,290
Noncurrent Liabilities
Long-term debt and lease obligation 29,31038,42240,30750,12117,309 
Long-term debt, excluding current maturities 29,31036,56237,97747,22317,309 
Liabilities, other than long-term debt20,14116,91217,9813,00021,01151
Deferred revenue and credits 51
Deferred revenue13,55714,56015,616 
Other liabilities 6002,3522,3653,0001,231 
Operating lease, liability5,9841,8602,3302,898
Derivative instruments and hedges, liabilities     19,780 
Total noncurrent liabilities:49,45155,33458,28853,12138,32051
Total liabilities:83,98878,99273,17664,64159,9835,341
Equity
Equity, attributable to parent96,368184,38018,5418,33011,68713,336
Common stock3434181097439
Additional paid in capital766,899752,602528,362472,667374,766323,284
Accumulated other comprehensive income786841841840838833
Accumulated deficit(671,351)(569,097)(510,680)(465,286)(363,991)(310,820)
Total equity:96,368184,38018,5418,33011,68713,336
TOTAL LIABILITIES AND EQUITY:180,356263,37291,71772,97171,67018,677

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
6/30/2018
6/30/2017
Revenues41,40436,93934,43720,3652,9617,539
Revenue, net 7,539
Cost of revenue
(Cost of Goods and Services Sold)
 (1,949)(1,278)    
Other undisclosed gross profit      
Gross profit:39,45535,66134,43720,3652,9617,539
Operating expenses(141,041)(92,215)(71,727)(68,226)(29,235)(26,115)
Other undisclosed operating income1,9491,278    
Operating loss:(99,637)(55,276)(37,290)(47,861)(26,274)(18,576)
Nonoperating income (expense)(2,617)(3,141)(8,104)(8,932)(26,177)91
Investment income, nonoperating     (26,278) 
Other nonoperating income2,131292581,05410191
Interest and debt expense(1,559)2,065(905)(3,810)(720) 
Loss from continuing operations before equity method investments, income taxes:(103,813)(56,352)(46,299)(60,603)(53,171)(18,485)
Other undisclosed income (loss) from continuing operations before income taxes1,559(2,065)9053,810  
Loss from continuing operations:(102,254)(58,417)(45,394)(56,793)(53,171)(18,485)
Loss before gain (loss) on sale of properties:(58,417)(45,394)(56,793)(53,171)(18,485)
Other undisclosed net loss      
Net loss:(102,254)(58,417)(45,394)(56,793)(53,171)(18,485)
Other undisclosed net income attributable to parent      
Net loss available to common stockholders, diluted:(102,254)(58,417)(45,394)(56,793)(53,171)(18,485)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
6/30/2018
6/30/2017
Net loss:(102,254)(58,417)(45,394)(56,793)(53,171)(18,485)
Other comprehensive income (loss)(55) 115(19)
Comprehensive loss:(102,309)(58,417)(45,393)(56,792)(53,166)(18,504)
Other undisclosed comprehensive income, net of tax, attributable to parent      
Comprehensive loss, net of tax, attributable to parent:(102,309)(58,417)(45,393)(56,792)(53,166)(18,504)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: